Table 4.
Safety events with tofacitinib treatment during the follow-up
| Adverse events / serious adverse events | Number of events (N = 26) | Incidence rate (IR) per 100 patient-years (PY) |
|---|---|---|
| Adverse events | ||
| Dyslipidemia | ||
| Asthenia and fatigue | ||
| Mild to moderate infections | ||
| Herpes simples | 1 | 0.31 |
| Urinary infection | 2 | 0.63 |
| Acute upper respiratory tract infections | 1 | 0.31 |
| COVID-19 | 1 | 0.31 |
| Folliculitis | 1 | 0.31 |
| Serious Adverse Events | ||
| Colectomy | 10 | 3.1 |
| Prostatic cancer | 1 | 0.31 |
| Significant increase in liver transaminases | 1 | 0.31 |
| Herpes zoster | 2 | 0.63 |
| Cellulitis | 1 | 0.31 |
| Cytomegalovirus colitis | 1 | 0.31 |
| Clostridioides difficile colitis | 1 | 0.31 |